227751-46-4 Usage
Chemical class
Naphthyridine derivatives This compound belongs to a group of chemical compounds derived from naphthyridine, a type of fused heterocyclic compound.
Formation
Esterification reaction 1,8-Naphthyridine-2-pentanoic acid methyl ester is formed by the reaction between 1,8-Naphthyridine-2-pentanoic acid and methanol, resulting in the formation of an ester.
Functional groups
Ester, carboxylic acid, and aromatic ring The molecule contains an ester functional group (-COOCH3), a carboxylic acid group (-COOH), and an aromatic ring structure.
Application
Organic synthesis This compound is used as a building block in the synthesis of various pharmaceutical and agrochemical compounds.
Potential uses
Biological activities and pharmacological properties 1,8-Naphthyridine-2-pentanoic acid methyl ester may have potential biological activities and is being studied for its pharmacological properties.
Stability
Stable compound The methyl ester form of the compound is stable and can be used in various chemical reactions and processes.
Solubility
Soluble in organic solvents This ester is likely to be soluble in organic solvents such as ethanol, methanol, and dichloromethane, due to its nonpolar nature.
Reactivity
Reactive towards nucleophiles and acids The ester functional group in the molecule can undergo hydrolysis in the presence of nucleophiles or acids, leading to the formation of the corresponding carboxylic acid or other products.
Structural features
Fused heterocyclic ring system The naphthyridine core consists of a fused six-membered and five-membered nitrogen-containing heterocycle, which contributes to the compound's unique properties and reactivity.
Synthesis
Multi-step process The synthesis of 1,8-Naphthyridine-2-pentanoic acid methyl ester typically involves a multi-step process, starting from simpler precursors and building up the complex structure through various chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 227751-46-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,7,7,5 and 1 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 227751-46:
(8*2)+(7*2)+(6*7)+(5*7)+(4*5)+(3*1)+(2*4)+(1*6)=144
144 % 10 = 4
So 227751-46-4 is a valid CAS Registry Number.
227751-46-4Relevant articles and documents
Non-peptide αvβ3 antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics
Coleman, Paul J.,Askew, Ben C.,Hutchinson, John H.,Whitman, David B.,Perkins, James J.,Hartman, George D.,Rodan, Gideon A.,Leu, Chih-Tai,Prueksaritanont, Thomayant,Fernandez-Metzler, Carmen,Merkle, Kara M.,Lynch, Robert,Lynch, Joseph J.,Rodan, Sevgi B.,Duggan, Mark E.
, p. 2463 - 2465 (2002)
Potent non-peptidic αvβ3 antagonists have been prepared where deletion of an amide bond from an earlier series of linear RGD-mimetics provides a novel series of chain-shortened αvβ3 antagonists with significantly improved oral pharmacokinetics. These chain-shortened αvβ3 antagonists represent structurally novel integrin inhibitors.
RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE
-
, (2020/07/25)
The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha ( EPAS1 ) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.
N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
-
, (2018/03/28)
The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.
